- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03752814
SYNOSTE Nitinail System Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The SYNOSTE Nitinail System (SNS) is an assembly of an active implantable distraction nail (SYNOSTE Nitinail), Locking screws, accessory instruments for surgery and the home care unit (also External control unit (ECU) or Halo). It includes also, a software tool, Syndex, that supports setting up the number of lengthening activations needed per day.
The SNS is intended for lengthening of the femur by distraction osteogenesis.
The study will consist of a recruitment period of 3 months and an observation period of roughly 24 months (6 months after explantation). The observation period is split in two parts: The first part contains the most critical treatment phases from implantation surgery of the device through the actual lengthening phase up to the end of the bone healing. The second part contains only two visits: the explantation surgery of the device and a control at 6 months of further follow-up.
After the fist part of the trial, a primary analysis of the data including the hypothesis testing will be carried out. After the second part of the trial a follow-up analysis will be done.
16 (max 20) patients will be recruited in Finland and Turkey.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Indication for femoral lengthening from different etiologies of max. 70 mm at single lengthening
- 18 to 65 years regardless of gender
- Suitable anatomy for SNS
- Able and willing to comply with study procedures
Exclusion Criteria:
- Other electronic implants
- Other Metallic implants in the affected limb below the osteotomy level
- Need for Magnetic Resonance imaging during the study
- BMI>30kg/m2 or weight>100kg
- Smoker
- Known hypersensitivity to Co, Ni, Cr or Ti metals
- Known hypersensitivity to Poly-Ether-Ether-Ketone (PEEK) or Ultrahigh Molecular Weight Poly-Ethylene (UHMWPE)
- Open growth plates
- Malignancy or tumor in bone
- Osteitis or soft tissue infection
- Significant existing deficit in range of motion of the adjacent joints
- Pseudoarthrosis
- Pregnancy
- Low psychological compliance (e.g. drug abuse)
- Simultaneous bilateral lengthening
- Need for osteotomies at multiple levels
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SYNOSTE Nitinail System
The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
|
Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lengthening control index (LCI)
Time Frame: 2,5 months
|
The primary objective is to verify whether the leg-lengthening procedure can be adequately controlled with the SNS system as measured with the lengthening control index (LCI) at the end of the distraction period defined as LCI = DIachieved / DIscheduled ,where DIachieved = Achieved distraction index, ie. the daily rate of distraction has on average occurred during the lengthening phase in mm/d. DIscheduled = mean scheduled lengthening rate in mm/day. Analyzed at primary analysis. |
2,5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance of Nitinail/Mechanical stability of Nitinail
Time Frame: 6-9 months
|
Mechanical stability of Nitinail as defined by the ratio of the numbers of breakages (nail and screws) to total nails implanted (% and absolute values) at the end of consolidation
|
6-9 months
|
Performance of Nitinail/Nitinail lengthening target achieved (%)
Time Frame: 2,5 months
|
Nitinail lengthening target achieved as defined by % of targeted lengthening achieved by Nitinail determined at the end of lengthening period
|
2,5 months
|
Performance of Nitinail/Nitinail lengthening target achieved (absolute value)
Time Frame: 2,5 months
|
Nitinail lengthening target achieved as defined by absolute value of targeted lengthening achieved by Nitinail determined at the end of lengthening period
|
2,5 months
|
Performance of Nitinail/Translation of nail lengthening to bone lengthening (%)
Time Frame: 2,5 months
|
Translation of nail lengthening to bone lengthening as % of the Bone gap increase from achieved lengthening of Nitinail determined at the end of lengthening period
|
2,5 months
|
Performance of Nitinail/Translation of nail lengthening to bone lengthening (absolute value)
Time Frame: 2,5 months
|
Translation of nail lengthening to bone lengthening as absolute value of the Bone gap increase from achieved lengthening of Nitinail determined at the end of lengthening period
|
2,5 months
|
Performance of Nitinail/Retention of achieved length by Nitinail
Time Frame: 6-9 months
|
Retention of achieved length by Nitinail as change of achieved lengthening of Nitinail between end of distraction and end of consolidation
|
6-9 months
|
Patient Reported Outcomes/Patient Satisfaction
Time Frame: 6-9 months AND 24 months
|
Patient satisfaction as the overall satisfaction value from Numeric Rating Scale at end of consolidation and final follow-up.
The NRS for overall outcomes is a undimensional measure of satisfaction intensity, where the patient selects among 0-10 integers to describe the intensity of their overall satisfaction with the treatment outcomes on a horizontal line.
"0" represents completely dissatisfied and "10" fully satisfied
|
6-9 months AND 24 months
|
Patient Reported Outcomes/Patient Satisfaction (aesthetic outcomes)
Time Frame: 6-9 months AND 24 months
|
Patient satisfaction as the aesthetic outcomes value from Numeric Rating Scale (NRS) at end of consolidation and final follow-up.
The NRS for aesthetic outcomes is a undimensional measure of satisfaction intensity, where the patient selects among 0-10 integers to describe the intensity of their satisfaction with the aesthetic outcomes on a horizontal line.
"0" represents completely dissatisfied and "10" fully satisfied.
|
6-9 months AND 24 months
|
Patient Reported Outcomes/Change in scores of 36-Item Short Form Survey (SF-36)
Time Frame: 6-9 months AND 24 months
|
Change in scores of SF-36 from preoperative baseline to end of consolidation for Primary analysis and to last visit for the Follow-up analysis.
The used version of the SF-36 is the RAND 36-item health survey 1.0 (1993) with a time frame of 4 weeks.
The SF-36 is an established and widely used set of generic, coherent, and easily administered quality-of-life measures in adults.
Scoring will be done according to the instructions provided by RAND.
Single item scores as well as health concept scale scores range from 0 to 100.
A higher score defines a more favorable health state, with a value of 100 representing full health.
|
6-9 months AND 24 months
|
Patient Reported Outcomes/Patient pain status
Time Frame: 2,5 months
|
Patient pain status as change of Numeric Rating Scale (NRS) from preoperative baseline to End of distraction (2,5 months).
The NRS for pain is a undimensional measure of pain intensity, where the patient selects among 0-10 integers to describe the intensity of their pain on a horizontal line.
"0" represents no pain and "10" worst possible pain.
|
2,5 months
|
Patient Reported Outcomes/Patient pain status
Time Frame: 24 months
|
Patient pain status as the pain profile of the Numeric Rating Scale (as described above) during the treatment (until 24 months)
|
24 months
|
Patient Reported Outcomes/Patient pain status (consumption of pain medication)
Time Frame: 24 months
|
Patient pain status as consumption of pain medication
|
24 months
|
Patient Reported Outcomes/Length of sick leave due to treatment
Time Frame: 6-9 months AND 24 months
|
Length of sick leave due treatment in days assessed until the end of consolidation and end of treatment for Primary and Follow-up analyses, respectively
|
6-9 months AND 24 months
|
Clinical Success of Treatment/Femur lengthening target achieved (%)
Time Frame: 6-9 months AND 24 months
|
Femur lengthening target achieved as % of the achieved femoral length increase of the targeted femoral length increase in mm determined at the end of consolidation and end of treatment for Primary and Follow-up analyses
|
6-9 months AND 24 months
|
Clinical Success of Treatment/Femur lengthening target achieved (absolute value)
Time Frame: 6-9 months AND 24 months
|
Femur lengthening target achieved as absolute value of the achieved femoral length increase of the targeted femoral length increase in mm determined at the end of consolidation and end of treatment for Primary and Follow-up analyses
|
6-9 months AND 24 months
|
Clinical Success of Treatment/Weight bearing index
Time Frame: 6-9 months
|
Weight bearing index as time to final full weight bearing (in days) per the achieved femoral length increase (in cm)
|
6-9 months
|
Clinical Success of Treatment/Consolidation index
Time Frame: 6-9 months
|
Consolidation index as time to radiological confirmation of 3 cortices bridging the bony gap (in days) per the achieved femoral length increase (in cm)
|
6-9 months
|
Clinical Success of Treatment/Knee and hip joint Range of Motion (ROM)
Time Frame: 6-9 months AND 24 months
|
Knee and hip joint Range of Motion (ROM) as flexion and extension at preoperative baseline, End of distraction and End of consolidation and compared to normal population values
|
6-9 months AND 24 months
|
Nitinail System Safety/Number and type of device related (Serious)Adverse Events
Time Frame: (6-9 months AND 24 months)
|
Number and type of device related (Serious)Adverse Events reported until the end of consolidation and end of treatment.
|
(6-9 months AND 24 months)
|
Nitinail System Safety/Duration of surgery
Time Frame: 10 days and 18 months
|
Duration of surgery of Nitinail related surgeries from cut-to- closure in minutes
|
10 days and 18 months
|
Nitinail System Safety/Length of hospital stay
Time Frame: 10 days and 18 months
|
Length of hospital stay of Nitinail related surgeries in days the patient spent in hospital perioperatively.
|
10 days and 18 months
|
Nitinail System Safety/Patient compliance to lengthening protocol
Time Frame: 2,5 months
|
Patient compliance to lengthening protocol as ratio of lengthening periods with non- compliance to protocol with all lengthening periods with one patient.
|
2,5 months
|
Nitinail System Safety/Release of metallic ions from the Nitinail
Time Frame: 3 months/further monitoring up to 24 months
|
Release of metallic ions from the Nitinail as Cobalt and Chromium ion concentrations in blood from preoperative baseline to end of distraction.
|
3 months/further monitoring up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Metin Küçükkaya, Prof. Dr., Şişli Florence Nightingale Hospital, Şişli/İstanbul, Turkey
- Principal Investigator: Jan Lindahl, Dr., HUCH Ortopedics and Traumatology, Töölö Hospital, Finland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leg Length Inequality
-
University College, LondonUnknownLeg Length Discrepancy | Leg Length DifferenceUnited Kingdom
-
Taipei Veterans General Hospital, TaiwanUnknownLeg Length Discrepancy, Shoe Lifts
-
Hospital for Special Surgery, New YorkThe Hospital for Sick Children; Boston Children's HospitalRecruitingLeg Length DiscrepancyUnited States, Canada
-
Sundsvall HospitalCompletedOsteoarthritis | Hip Arthroplasty | Leg Length Difference
-
National Taiwan University HospitalNational Science Council, TaiwanCompletedScoliosis | Leg Length DiscrepancyTaiwan
-
Orthofix s.r.l.CompletedJoint Diseases | Genu Varum | Genu Valgum | Knee Deformity | Ankle Deformity | Length Inequality, Leg | Discrepancy Length; Congenital | Deformity of LimbItaly
-
Hadassah Medical OrganizationAmorficalUnknownLeg Length Discrepancy | Skeletal DeformitiesIsrael
-
Poznan University of Medical SciencesCompletedLeg Length InequalityPoland
-
University of PecsRecruiting
-
Assiut UniversityUnknownTotal Knee ReplacementEgypt
Clinical Trials on SYNOSTE Nitinail System
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting